40
Participants
Start Date
October 25, 2018
Primary Completion Date
June 30, 2022
Study Completion Date
January 15, 2024
Ocoxin-Viusid
"An oral solution of Oncoxin® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT up to 3 weeks after finishing the treatment.~The treatment with Oncoxin®-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously for approximately 29 weeks from the patient's inclusion in the study."
National Institute of Oncology and Radiobiology (INOR), Havana
Catalysis SL
INDUSTRY